Möchten Sie immer auf dem neuesten Stand bleiben?

Hengrui Pharma and Kailera Therapeutics announce clinical data presentations at the American Diabetes Association 86th Scientific Sessions

SAN JOSE, Calif., May 12, 2026 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral...

Novel alternative to GLP-1 drugs: Phase I data demonstrate fat mass reduction, preservation of lean mass, 80% responder rate, and no serious adverse events

Higher-dose Wegovy led to up to 28% weight loss, mainly from fat, with muscle preserved, new trial data show.

Reported positive results from aleniglipron Phase 2 ACCESS II study with up to 16.3% body weight loss, demonstrating highest efficacy among oral GLP-1RAs at the 44-week time point and potentially...

Dublin, April 30, 2026 (GLOBE NEWSWIRE) -- The "Deoxycholic Acid Obesity Drugs Market Report 2026" has been added to ResearchAndMarkets.com's offering. The deoxycholic acid obesity drugs market...

UPDATED: NorthStrive Biosciences Files New U.S. Patent Application Covering EL-22 Formulations and Dosing for Treatment of Muscle-Wasting Conditions relate

NorthStrive Biosciences Files New U.S. Patent Application for EL-22 Targeting Muscle Preservation in Humans

In SYNCHRONIZE-1, participants lost up to an average of 39.2 lb (17.8 kg) from baseline after 76 weeks of treatment with survodutide, a glucagon/GLP-1 receptor dual agonist1The trial met both weight...

Copenhagen, Denmark, 23 April 2026 – Antag Therapeutics (“Antag” or “the Company”), advancing personalized and flexible obesity treatment through GIP receptor antagonism, today announces that it will...